Received May 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 4n222 | IM / LA |
66 years old patient received priorix; Drug administered via inappropriate route; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of subcutaneous injection formulation administered by other route in a 66-year-old female patient who received MMR (Priorix) (batch number 4n222, expiry date 13-SEP-2026) for prophylaxis. On 15-MAY-2025, the patient received the 1st dose of Priorix (intramuscular, left arm). On 15-MAY-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Drug administered via inappropriate route). On an unknown date, the patient experienced inappropriate age at vaccine administration (Verbatim: 66 years old patient received priorix). The outcome of the subcutaneous injection formulation administered by other route and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-MAY-2025 The reporter reported that the 66 years old patient received 1st dose of Priorix intramuscularly which led to inappropriate age at vaccine administration and subcutaneous injection formulation administered by other route.